ahpba sponsored consensus conference on the multidisciplinary treatment of bile duct cancer
DESCRIPTION
TRANSCRIPT
AHPBA Sponsored Consensus Conference on the
Multidisciplinary Treatment of Bile Duct Cancer
Wednesday, January 15, 2014San Francisco Marriott Marquis55 Fourth StreetSan Francisco, California
Multidisciplinary Treatment of Bile Duct Cancer (BDC)Wednesday, January 15, 2014 San Francisco Marriott Marquis
55 Fourth Street • San Francisco, California
GoalThe focus of this consensus conference is the multidisciplinary management of patients with bile duct cancers. The aim of this conference is to review the current indications for surgical treatment, non-surgical interventions, and adjuvant therapy for bile duct cancer. This topic has not previously been discussed in a consensus conference format, and therefore, there is likely to be a high education yield for participants. The format will divide the conference into three sessions, individually focusing on Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer. The program features an expert multispecialty international group of speakers, panelists,
and moderators with extensive experience in the diagnosis, staging, treatment, and research related to the state-of-the-art treatment of patients with bile duct malignancy. The goal of this meeting is to provide a forum to review, discuss, and establish current practice guidelines and consensus statements. At the conclusion of the conference, attendees should leave with a higher level of understanding and competence in the diagnosis and management of these disorders.
Educational ObjectivesAfter attending the conference, participants should be able to- Appropriately apply diagnostic and staging modalities to bile duct cancer patients (Knowledge,
Competence, Performance);- Appropriately select the proper surgical treatment modalities available for the
management of bile duct cancer (Knowledge, Competence, Performance);- Appropriately select and sequence the best multiple interventional and nonsurgical treatment
modalities available for optimal management of bile duct cancer (Knowledge, Competence, Performance, Patient Outcomes);
- Appropriately implement the most up-to-date systemic cytotoxic and biologic strategies in the management of bile duct cancer to improve patient outcomes (Knowledge, Competence, Performance, Patient Outcomes).
Target AudienceThis conference will be beneficial to surgical oncologists, medical oncologists, radiologists, and interventional radiologists.
Educational MethodsLectures – Question and Answer – Panel Discussions – Videos
EvaluationA course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvements activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.
Accreditation/Credit DesignationThis activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and The Americas Hepato-Pancreato-Biliary Association. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 7.50 AMA/PRA Category 1 Credits TM . Physicians should only claim the credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance Verification CertificatesCertificates awarding AMA/PRA Category 1 Credit TM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.
Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
* Not an official event of the 2014 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the 2014 Gastrointestinal Cancers Symposium.
Thomas A. Aloia, MD, Co-ChairThe University of TexasMD Anderson Cancer CenterHouston, Texas
John C. Mansour, MD, Co-ChairThe University of Texas Southwestern Medical CenterDallas, Texas
Sharon M. Weber, MD, Co-ChairUniversity of WisconsinMadison, Wisconsin
Eren Berber, MDCleveland ClinicCleveland, Ohio
William C. Chapman, MDWashington University School of MedicineSt. Louis, Missouri
Alessandro Landskron Diniz, MDAC Camargo Cancer CenterSao Paulo, Brazil
Cristina R. Ferrone, MDMassachusetts General HospitalBoston, Massachusetts
William Hawkins, MDWashington University School of MedicineSt. Louis, Missouri
William R. Jarnagin, MDMemorial Sloan-Kettering Cancer CenterNew York, New York
Byrne Lee, MDCity of HopeDuarte, California
Shishir K. Maithel, MDEmory UniversityAtlanta, Georgia
Program Planning CommitteeNipun B. Merchant, MDVanderbilt University Medical CenterNashville, Tennessee
Carl R. Schmidt, MDThe Ohio State UniversityColumbus, Ohio
Jean-Nicolas Vauthey, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas
Theodore H. Welling, III, MDUniversity of MichiganAnn Arbor, Michigan
Adam Yopp, MDUniversity of Texas Southwestern Medical CenterDallas, Texas
George Zogopoulos, MD, PhDMcGill UniversityMontreal, QuebecCanada
Jill KawulokAHPBALeawood, Kansas
Nonie LowryAHPBALeawood, Kansas
Brigitte M. Taylor, CAPThe University of TexasMD Anderson Cancer CenterHouston, Texas
Constance C. Tierney, CMPThe University of TexasMD Anderson Cancer CenterHouston, Texas
ProgramWednesday, January 15, 2014
7:00–7:50 a.m. Continental Breakfast/Registration
7:50–8:00 Introduction William C. Chapman, MD
8:00–10:30 SESSION I: GALLBLADDER CANCER Moderators: Felipe José Fernández Coimbra, MD;
William R. Jarnagin, MD Panelists: Rachna T. Shroff, MD; Elijah Dixon, MD;
Jennifer Knox, MD
8:00–8:20 Pathologic Evaluation for Patients With Gallbladder Polyps and Suspicion of Early Stage Gallbladder Cancer
Juan Carlos Roa, MD, MSc
8:20–8:30 Discussion
8:30–8:50 Evaluation and Management of the Patient Presenting With a Gallbladder Mass
Nicolas Járufe Casis, MD
8:50–9:00 Discussion
9:00–9:20 Incidentally Discovered Gallbladder Cancer:
The Gallbladder is Out, Now What Do We Do?
Shishir K. Maithel, MD
9:20–9:30 Discussion
9:30–9:50 Advances in Neoadjuvant and Adjuvant Chemotherapy and Radiation
Approaches to Gallbladder Cancer Milind Javle, MD
9:50–10:00 Discussion
10:00-10:30 Break
10:30a.m.–12:30 p.m. SESSION II: INTRAHEPATIC CHOLANGIOCARCINOMA (IHCCA) Moderators: Masaru Miyazaki, MD; Sharon M. Weber, MD Panelists: Ghassan K. Abou-Alfa, MD; Michael A. Choti, MD, MBA;
Michael I. D’Agelica, MD; Jeff Geschwind, MD
10:30–10:50 Recommendations for Diagnosis and Staging of IHCCA Timothy M. Pawlik, MD, MPH, PhD
10:50–11:00 Discussion
11:00–11:20 Local-Regional Treatment Strategies for IHCCA Dario Ribero, MD
11:20–11:30 Discussion
11:30–11:50 Hepatocholangiocarcinoma: Defining and Treating An Emerging Entity
Norihiro Kokudo, MD, PhD
11:50–Noon Discussion
Noon–12:20 Chemotherapy and Radiation Therapy for IHCCA Eileen M. O’Reilly, MD
12:20–12:30 p.m. Discussion
12:30–1:30 Lunch at the Movies: Case Presentations With Video Moderators: David M. Nagorney, MD; Paul D. Greig, MD Invited Presenters: Thomas A. Aloia, MD; Julie K. Heimbach, MD;
William R. Jarnagin, MD; Nicolas Járufe Casis, MD; Norihiro Kokudo, MD, PhD; Masaru Miyazaki, MD; Masato Nagino, MD
1:30–3:30 SESSION III: HILAR CHOLANGIOCARCINOMA Moderators: John C. Mansour, MD; Jean-Nicolas Vauthey, MD Panelists: Alessandro Landskron Diniz, MD; Christopher E. Forsmark, MD
Andrew X. Zhu, MD, PhD 1:30–1:50 Multimodality Evaluation of Patients With Suspected
Hilar Cholangiocarcinoma: Including When to Proceed Without a Tissue Diagnosis
Thomas A. Aloia, MD
1:50–2:00 Discussion
2:00–2:20 Transplantation for Hilar Cholangiocarcinoma With and Without PSC
Julie K. Heimbach, MD
2:20–2:30 Discussion
2:30–2:50 Resectional Strategies for Hilar Cholangiocarcinoma Including Vascular Resection and the Concept of ‘No-Touch’ Masato Nagino, MD
2:50–3:00 Discussion
3:00–3:20 Traditional and Novel Chemotherapy and Radiation Approaches to Hilar Cholangiocarcinoma
Christopher Crane, MD
3:20–3:30 Discussion
3:30–3:40 p.m Closing Comments Sharon M. Weber, MD
Ghassan K. Abou-Alfa, MDMemorial Sloan-Kettering Cancer CenterWeill Medical College at Cornell UniversityNew York, New York
Thomas A. Aloia, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas
William C. Chapman, MDWashington University School of MedicineSt. Louis, Missouri
Michael A. Choti, MD, MBAUniversity of Texas SouthwesternDallas, Texas
Felipe José Fernández Coimbra, MDAC Camargo HospitalSao Paulo, Brazil
Christopher Crane, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas
Michael I. D’Angelica, MDMemorial Sloan-Kettering Cancer HospitalNew York, New York
Alessandro Landskron Diniz, MDAC Camargo Cancer CenterSao Paulo, Brazil
Elijah Dixon, MDUniversity of CalgaryCalgary, Alberta, Canada
Christopher E. Forsmark, MDUniversity of Florida College of MedicineGainesville, Florida
Jeff Geschwind, MDJohns Hopkins UniversitySchool of MedicineBaltimore, Maryland
Paul D. Greig, MDUniversity of TorontoToronto, Ontario, Canada
Julie K. Heimbach, MDMayo ClinicRochester, Minnesota
William R. Jarnagin, MDMemorial Sloan-Kettering Cancer CenterNew York, New York
Nicolas Járufe Casis, MDPontificia Unversidad Catolica de ChileSantiago, Chile
Milind Javle, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas
Registration InformationOn-site registration opens at 7:00 a.m. on Wednesday, January 15, 2014 at the San Francisco Marriott Marquis. The opening session of the conference will begin at 7:50 a.m. and the conference will adjourn at 3:40 p.m. on Wednesday, January 15, 2014. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.
The deadline for advance registration is January 6, 2014.
There are three ways to register:• Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexas
MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439• Faxto:713-794-1724• On-lineatwww.mdanderson.org/conferences
We accept the following forms of payment:• Check(payablethroughU.S.banksonly)• MoneyOrder• CreditCards(MasterCard,VISA,andAmericanExpress)• Cash(on-siteregistration)
A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.
The full conference registration fee includes the tuition, abstract book, breaks, and lunch.
Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 6, 2014. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.
The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified either by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.
The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.
For additional information, contact CME/Conference Management at 713-792-2223 or 866-849-5866.
Jennifer Knox, MD, MScUniversity of Toronto Princess MargaretToronto, Ontario, Canada
Norihiro Kokudo, MD, PhDUniversity of Tokyo Graduate School of MedicineTokyo, Japan
Shishir K. Maithel, MDEmory UniversityAtlanta, Georgia
John C. Mansour, MDUniversity of Texas Southwestern Medical CenterDallas, Texas
Masaru Miyazaki, MDChiba University Graduate School of MedicineChiba, Japan
Masato Nagino, MD, PhDNagoya University Graduate School of MedicineNagoya, Japan
David M. Nagorney, MDMayo Clinic College of MedicineRochester, Minnesota
Eileen M. O’Reilly, MDMemorial Sloan-Kettering Cancer CenterNew York, New York
Timothy M. Pawlik, MD, MPH, PhDJohns Hopkins HospitalBaltimore, Maryland
Dario Ribero, MDOspedale Ordine Mauriziano “Umberto I”Torino, Italy
Juan Carlos Roa, MD, MScPontificia Universidad Catolica de ChileSantiago, Chile
Rachna T. Shroff, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas
Jean-Nicolas Vauthey, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas
Sharon M. Weber, MDUniversity of WisconsinMadison, Wisconsin
Andrew X. Zhu, MD, PhDMassachusetts General HospitalHarvard Medical SchoolBoston, Massachusetts
Faculty
Special AssistanceContact the Department of CME/Conference Management at 713-792-2223 or 866-849-5866 if you have any special dietary or ADA accommodation needs.
AccommodationsIf you are attending the 2014 Gastrointestinal Cancers Symposium, hotel rooms are available at the San Francisco Marriott Marquis, 55 Fourth Street, San Francisco, California. Reserve a room through the Symposium website at gicasym.org.
Ground TransportationThe hotel is approximately 14 miles from San Francisco International Airport and 20 miles from the Oakland Airport. Taxis are available at the approximate price of $40 one way from SFO and $60 one way from Oakland. Super Shuttle is also available. Please call 415-558-8500 or book on line at www.supershuttle.com.
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.
Photographing, audio taping and videotaping are prohibited.
Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chair for consideration.
THIS
IS N
OT A
SEL
F-M
AILE
R
ADDR
ESS
TO:
AHPB
A Sp
onso
red
Cons
ensu
s Co
nfer
ence
on
the
Mul
tidis
cipl
inar
y Tr
eatm
ent o
f Bi
le D
uct C
ance
r
Depa
rtmen
t of C
ME/
Conf
eren
ce M
anag
emen
t – U
nit 1
381
The
Univ
ersi
ty o
f Tex
as M
D An
ders
on C
ance
r Cen
ter
PO B
ox 3
0143
9, H
oust
on, T
X 77
230-
1439
or fa
x to
713
-794
-172
4M
ake
chec
k or
mon
ey o
rder
pay
able
to:
The
Univ
ersi
ty o
f Tex
as M
D An
ders
on C
ance
r Cen
ter
FULL
CO
NFE
RE
NC
ER
EG
IST
RA
TIO
N F
EE
1 P
ostm
arke
d by
1/07
/14 .
........
...$ 2
60.00
1 P
ostm
arke
d af
ter 1
/07/
14 ...
....$ 3
00.00
1 Tr
aine
es ...
........
........
........
........
..$12
5.00
(m
ust p
rovid
e le
tter f
rom
Dire
ctor
)
CO
NFE
REN
CE
REG
ISTR
ATI
ON
- 06
38/1
1084
5/30
0706
38
AHPB
A Sp
onso
red
Cons
ensu
s Con
fere
nce o
n th
eM
ultid
iscip
linar
y Tre
atm
ent o
f Bi
le D
uct C
ance
r - Ja
nuar
y 15,
2014
Last
Nam
e
Fi
rst
M
I
H
ighe
st D
egre
e
Depa
rtmen
t (in
clud
e bo
x no
.)
Sp
ecia
lty
Inst
itutio
n
Ph
ysic
ian
Stre
et
City
S
tate
/For
eign
Cou
ntry
/Zip
or M
ail C
ode
Dayt
ime
Phon
e (w
ith a
rea
code
)
Cel
l Pho
ne (w
ith a
rea
code
)
F
ax (w
ith a
rea
code
)
E-m
ail A
ddre
ss (
plea
se p
rint)
Char
ge th
e fo
llow
ing:
oVI
SA
o
Mas
terC
ard
oAm
eric
an E
xpre
ss
Cred
it Ca
rd N
umbe
r
Exp
iratio
n Da
te
Busi
ness
Uni
t
D
epar
tmen
t
Fun
d Gr
oup*
F
und
F
und
Type
Cred
it Ca
rd H
olde
r Nam
e (F
irst/
Last
)
Cre
dit C
ard
Hold
er B
illin
g Ad
dres
s &
ZIP
Cod
e
Auth
orize
d Si
gnat
ure
REQU
IRED
for c
redi
t car
d or
IDT
MD
Ande
rson
Em
ploy
ee ID
No.
(REQ
UIRE
D)
IDT
Appr
over
Nam
e (F
irst/
Last
) ple
ase
prin
t
I
DT A
ppro
ver E
-mai
l
oYe
s
o
No
MD
And
erso
n In
terd
epar
tmen
tal T
rans
fer (
IDT)
No.
: *F
und
Grou
p 90
will
not
be
acce
pted
Emer
genc
y Co
ntac
t
P
hone
(with
are
a co
de)
Depa
rtmen
t of C
ME/
Conf
eren
ce M
anag
emen
t - U
nit 1
381
The
Univ
ersi
ty o
f Tex
as M
D An
ders
on C
ance
r Cen
ter
# 17
6700
/110845/30070638
PO B
ox 3
0143
9Ho
usto
n, T
X 77
230-
1439
Non
-Pro
fit O
rg.
U.S.
Pos
tage
P A
I DHo
usto
n, T
XPe
rmit
No.
705
2